Here are relevant reports on : food-allergy-therapeutics-market
-
Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market – (Pipeline Forecast & Market Forecast in G8 Countries) (2011 – 2020)
The incidence of acute lymphocytic leukemia is high in children from 0 to 14 years than the people aged above 14. It is the most common childhood acute lymphocytic leukemia. However, the acute lymphocytic leukemia may also occur in adults. Acute lymphocytic leukemia distribution depends on age. For instance, 30% of is diagnosed before the age of 5 and 55% of ALL age 15.The acute lymphocytic leukemia market is segmented into two types; namely childhood acute lymphocytic leukemia, and adult acute lymphocytic leukemia. The market was dominated by Hyper-CVAD regimen in 2010. However, in 2020, the market is expected to be equally dominated by Hyper-CVAD and Linker regimen.
- Published: December 2013
- Price: $ 4950
- TOC Available:
-
Chronic Lymphocytic Leukemia Therapeutics Market in G8 Countries (2010 - 2020)
Chronic lymphocytic leukemia is the second most common cancer in adult males and rarely occurs in children. The risk of chronic lymphocytic leukemia is closely associated with age. About 90% of chronic lymphocytic leukemia is diagnosed in middle age. Incidence rate of CLL is high in men and women over 50 years of age. The chronic lymphocytic leukemia market is segmented into two types; namely childhood chronic lymphocytic leukemia and adulthood lymphocytic leukemia. The market was dominated by Campath drug in 2010. However, in 2020, the market is expected to be equally dominated by GA101/RG7159 molecule and Arzerra drug.
- Published: December 2011
- Price: $ 4950
- TOC Available:
-
Lung Cancer Therapeutics Market (NSCLC & SCLC) - 2010-2020 (Pipeline Assessment and Market Forecast) in G7 countries
Lung cancer is responsible for most of the deaths (due to cancer) across the globe. With just one drug slated to be launched by 2014 – Talactoferrin by Agennix AG, for patients with advanced lung cancer; having failed both chemotherapy and treatments with epidermal growth factor receptor (EFGR) - Tyrosine kinase inhibitor (TKI). Lung cancer is still an area with high unmet need for early diagnosis and limited treatment options in the advanced stages of lung cancer.
- Published: November 2011
- Price: $ 4950
- TOC Available:
-
Medical Automation Market by Application (Diagnostics & Monitoring, Therapeutics, Lab & Pharmacy Automation, Medical Logistics & Training), End-User (Hospital, Diagnostic Center, Research Institute, Home/Ambulatory Care) - Global Forecast to 2020
The global medical automation market over the forecast period of 2015 to 2020. The market is expected to reach USD 55.03 Billion by 2020, at CAGR of 9.5% from 2015 to 2020. Continuous technological advancements in automation solutions, increasing government financial support for medical automation, rising labour costs, and growing need for reproducibility and accuracy are key factors fuelling the growth of the medical automation market. Increasing demand for automation in laboratories and pharmacies and high potential for early detection and treatment of diseases due to automation are some other prime factors offering growth opportunities for players in the medical automation market. However, high cost of automation is one of the key restraints for this market.
- Published: February 2016
- Price: $ 4950
- TOC Available:
-
North America Injectable Drug Delivery Market – by Formulations [Liposomes, Microspheres, & Nanoparticles], Devices [Disposables & Reusable, Fillable & Prefilled, Pen, Needle Free & Auto Injectors] & Therapeutics [Diabetes & Oncology] – Forecasts to 2017
The North American injectable drug delivery technologies market was valued at $9.3 billion in 2012; it is expected to reach $16.6 billion by 2017 at a CAGR of 12.3% from 2012 to 2017. Injectable drug delivery technologies are the combination of two major segments; devices and formulations. The North American injectable drug delivery formulations technologies market was the largest segment in this market. In addition, the market is segmented on the basis of its therapeutic applications. In therapeutic area, hormonal disorders command the major segment of injectable drug delivery technologies market due to high demand of injectable in treatment of diabetes. However, auto-immune diseases are the fastest growing segment of this market due to the advent of biologics (tumor necrosis factor (TNF) and Interleukin 1 (IL-1)) and improving patient compliance by the development of self injection devices.
- Published: April 2013
- Price: $ 4950
- TOC Available:
-
Aptamers Market by Product Type (DNA, RNA, XNA), Technology (SELEX), Application (Therapeutics, Diagnostics, R&D), End Users (Pharmaceutical & Biotechnology Companies, Academic & Government Research Institutes, CROs) - Global Forecast to 2026
The global aptamers market growth is primed to transition from $151 million in 2021 to $342 million by 2026, showcasing a strong CAGR of 17.7%. Growth of the market is attributed to factors such as increase in number of clinical trials for development of aptamer-based therapeutics, increase in awareness about advantages of aptamers as compared to antibodies, rising investment in pharmaceutical R&D, and rising prevalence of chronic and rare diseases to increase the demand for aptamer-based therapeutics and diagnostics. Growth in the venture capital funding for research on aptamers and growing collaborations with research institutes and pharmaceutical companies are also expected to offer a wide range of growth opportunities to players in the market.
- Published: November 2021
- Price: $ 4950
- TOC Available:
-
Disposable Medical Device Sensors Market by Product (Biosensor, Image sensor, Accelerometer), Type (Strip Sensors, Invasive Sensors, Wearable Sensors), Application(Diagnostic Testing, Therapeutics, Patient Monitoring, Imaging) - Global Forecast to 2026
The global disposable medical device sensors market in terms of revenue was estimated to be worth $6.5 billion in 2021 and is poised to reach $9.4 billion by 2026, growing at a CAGR of 7.7% from 2021 to 2026. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market.
- Published: June 2021
- Price: $ 4950
- TOC Available:
-
Microfluidics Market by Product (Chip, Sensor, Valve, Pump, Needle), Material (Silicon, Polymer), Application [Diagnostics (Clinical, PoC), Research (Proteomics, Genomics, Cell), Therapeutics (Drug Delivery Wearables)], End User – Global forecast to 2030
The global Microfluidics market, valued at US$23.71 billion in 2024, stood at US$24.96 billion in 2025 and is projected to advance at a resilient CAGR of 8.3% from 2025 to 2030, culminating in a forecasted valuation of US$37.19 billion by the end of the period. Several significant factors are driving the growth of the microfluidics market, thereby enhancing its expansion and applications. There is a growing demand for point-of-care diagnostics, which require fast, accurate, and cost-effective instruments.
- Published: January 2026
- Price: $ 4950
- TOC Available:
-
Blood Collection Devices Market by Product (Tubes (Plasma (EDTA, Heparin), Serum), Needles & Syringes, Blood Bags, Monitors), Method (Manual, Automated), Application (Diagnostics, Therapeutics), End User (Hospitals, Blood Banks) - Global Forecast to 2030
The global blood collection devices market, valued at US$8.61 billion in 2024, stood at US$9.13 billion in 2025 and is projected to advance at a resilient CAGR of 7.4% from 2024 to 2030, culminating in a forecasted valuation of US$13.02 billion by the end of the period. The growing number of accidents and trauma cases has further increased the need for rapid and reliable blood collection for diagnostics and emergency care.
- Published: November 2025
- Price: $ 4950
- TOC Available:
-
Oligonucleotide Therapeutics Market by Molecule (Nusinersen, Vutrisiran, Inclisiran, Eteplisiran), Type (ASO, siRNA, Others), Disease Type (Neurology, Rare Diseases, Others), RoA (SC, Intrathecal, IV, Others), and Region - Global Forecast to 2030
The global oligonucleotide therapeutics market, valued at US$5.92 billion in 2024, stood at US$7.19 billion in 2025 and is projected to advance at a resilient CAGR of 19.7% from 2025 to 2030, culminating in a forecasted valuation of US$17.70 billion by the end of the period. The market is growing as more RNA-targeting therapies gain broader clinical acceptance. This increase is mainly driven by siRNAs and antisense candidates, supported by advances in delivery technologies like GalNAc conjugates and lipid nanoparticles.
- Published: January 2026
- Price: $ 4950
- TOC Available:
Records 11 to 20 of 50
